Brought to you by 
Savara buys fellow respiratory disease-focused firm Serendex
08 Sep 2020
Executive Summary
Expanding its pipeline of orphan respiratory therapies, Savara Pharmaceuticals is acquiring Danish firm Serendex Pharmaceuticals AS for an undisclosed sum in an all-stock deal, which also includes milestone-based earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com